Logotype for Medigene AG

Medigene (MDG1) investor relations material

Medigene Status Update summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Medigene AG
Status Update summary27 Nov, 2024

Strategic refocus and organizational realignment

  • Medigene is prioritizing R&D programs with the highest potential return, focusing on MDG3010 with WuXi Biologics and pausing other autologous cell therapy programs while seeking partnerships for them.

  • A workforce reduction of 40% and other cost-saving measures are being implemented to align with the new R&D focus.

  • Financial guidance and cash runway remain unchanged, extending to July 2025, with €9.5M in cash as of September 30, 2024.

  • The company is open to evaluating acquisition offers and is actively seeking partnerships and financing to extend the runway into 2026 and beyond.

  • Organizational realignment supports sustainable growth and long-term success.

Pipeline and partnership updates

  • MDG3010, a bispecific TCR TCE program with WuXi Biologics, is the lead focus, with proof-of-principle data expected in H2 2025.

  • MDG1015, a 3rd generation TCR-T therapy, received IND approval in Q3 2024; CTA submission is planned for Q4 2024, but trial initiation is delayed pending financing or partnerships.

  • All other autologous cell therapy programs are paused, with efforts to find partners for further development.

  • The WuXi Biologics partnership is a 50/50 research and collaboration agreement until lead candidate development, after which economics may shift.

  • Partnerships with BioNTech, Regeneron, and WuXi Biologics validate the platform and provide milestone and royalty opportunities.

Market and financial context

  • Investor and partner sentiment currently favors non-cellular, antibody-based bispecific approaches over preclinical autologous TCR-T therapies.

  • The bispecific therapies market is projected to grow at a 40.9% CAGR to over $80 billion by 2030.

  • Medigene is seeking business development, M&A, and non-dilutive capital opportunities, but cannot comment on the maturity of ongoing discussions.

  • Share price is considered undervalued, with potential for improvement tied to business development or M&A activity.

  • Revenue sources include upfront, milestone, R&D payments, and product sales.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

The essential earnings season companion

The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Medigene AG is a biotechnology company specializing in the development of T cell-based immunotherapies for cancer treatment. The company focuses on engineered T cell receptors (TCRs) and dendritic cell vaccines to enhance the body's immune response against tumors. Its research and development efforts aim to create innovative therapies that improve targeted cancer treatment options. The company is headquartered in Planegg, Germany, and its shares are listed on the Frankfurt Stock Exchange (FSE).

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage